Tags

Type your tag names separated by a space and hit enter

Adenoviral vector immunity: its implications and circumvention strategies.
Curr Gene Ther. 2011 Aug; 11(4):307-20.CG

Abstract

Adenoviral (Ad) vectors have emerged as a promising gene delivery platform for a variety of therapeutic and vaccine purposes during last two decades. However, the presence of preexisting Ad immunity and the rapid development of Ad vector immunity still pose significant challenges to the clinical use of these vectors. Innate inflammatory response following Ad vector administration may lead to systemic toxicity, drastically limit vector transduction efficiency and significantly abbreviate the duration of transgene expression. Currently, a number of approaches are being extensively pursued to overcome these drawbacks by strategies that target either the host or the Ad vector. In addition, significant progress has been made in the development of novel Ad vectors based on less prevalent human Ad serotypes and nonhuman Ad. This review provides an update on our current understanding of immune responses to Ad vectors and delineates various approaches for eluding Ad vector immunity. Approaches targeting the host and those targeting the vector are discussed in light of their promises and limitations.

Authors+Show Affiliations

Department of Comparative Pathobiology, Purdue University Center for Cancer Research, and Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

21453277

Citation

Ahi, Yadvinder S., et al. "Adenoviral Vector Immunity: Its Implications and Circumvention Strategies." Current Gene Therapy, vol. 11, no. 4, 2011, pp. 307-20.
Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011;11(4):307-20.
Ahi, Y. S., Bangari, D. S., & Mittal, S. K. (2011). Adenoviral vector immunity: its implications and circumvention strategies. Current Gene Therapy, 11(4), 307-20.
Ahi YS, Bangari DS, Mittal SK. Adenoviral Vector Immunity: Its Implications and Circumvention Strategies. Curr Gene Ther. 2011;11(4):307-20. PubMed PMID: 21453277.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adenoviral vector immunity: its implications and circumvention strategies. AU - Ahi,Yadvinder S, AU - Bangari,Dinesh S, AU - Mittal,Suresh K, PY - 2011/02/15/received PY - 2011/03/28/accepted PY - 2011/4/2/entrez PY - 2011/4/2/pubmed PY - 2011/10/1/medline SP - 307 EP - 20 JF - Current gene therapy JO - Curr Gene Ther VL - 11 IS - 4 N2 - Adenoviral (Ad) vectors have emerged as a promising gene delivery platform for a variety of therapeutic and vaccine purposes during last two decades. However, the presence of preexisting Ad immunity and the rapid development of Ad vector immunity still pose significant challenges to the clinical use of these vectors. Innate inflammatory response following Ad vector administration may lead to systemic toxicity, drastically limit vector transduction efficiency and significantly abbreviate the duration of transgene expression. Currently, a number of approaches are being extensively pursued to overcome these drawbacks by strategies that target either the host or the Ad vector. In addition, significant progress has been made in the development of novel Ad vectors based on less prevalent human Ad serotypes and nonhuman Ad. This review provides an update on our current understanding of immune responses to Ad vectors and delineates various approaches for eluding Ad vector immunity. Approaches targeting the host and those targeting the vector are discussed in light of their promises and limitations. SN - 1875-5631 UR - https://www.unboundmedicine.com/medline/citation/21453277/Adenoviral_vector_immunity:_its_implications_and_circumvention_strategies_ L2 - https://www.eurekaselect.com/74394/article DB - PRIME DP - Unbound Medicine ER -